Your browser doesn't support javascript.
Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics.
Kandimalla, Ramesh; John, Albin; Abburi, Chandrika; Vallamkondu, Jayalakshmi; Reddy, P Hemachandra.
  • Kandimalla R; Department of Biochemistry, Kakatiya Medical College, Warangal, Telangana, 506007, India.
  • John A; Applied Biology, CSIR-Indian Institute of Technology, Uppal Road, Tarnaka, Hyderabad, Telangana, 500007, India.
  • Abburi C; Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Vallamkondu J; University of Chicago, Chicago, IL, 60637, USA.
  • Reddy PH; National Institute of Technology, Warangal, Telangana, 506004, India.
Mol Neurobiol ; 57(10): 4106-4116, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-645016
ABSTRACT
The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to "flatten" the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. Graphical Abstract.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Protease Inhibitors / Viral Vaccines / Coronavirus Infections Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Mol Neurobiol Journal subject: Molecular Biology / Neurology Year: 2020 Document Type: Article Affiliation country: S12035-020-02022-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Protease Inhibitors / Viral Vaccines / Coronavirus Infections Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Mol Neurobiol Journal subject: Molecular Biology / Neurology Year: 2020 Document Type: Article Affiliation country: S12035-020-02022-0